Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...

The stocks listed here each increased their dividend payments by more than 10% recently. When you think of a great dividend ...

WeightWatchers has appointed Dr. Kim Boyd as chief medical officer and announced a new program focused on helping women ...

Walmart Inc. is giving $500,000 in grants and in-kind donations to Central Texas communities hit over the July Fourth weekend ...

A cargo ship attacked by Yemen’s Houthi rebels sank Monday in the Red Sea, the group said, raising new concerns over safety ...

The health of U.S. children has deteriorated over the past 17 years, with kids today more likely to have obesity, chronic ...

"Both Wegovy and Zepbound have demonstrated clinically significant weight reduction." "For example, if a patient has fatty liver, we will choose the GLP-1 that is proven to work best for liver ...

The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on average, compared ...

Nearly 32% of Zepbound users ultimately lost at least a quarter of their body weight, compared with just 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.